Glioma had the highest proportions of patients with level 3B alterations (70.6%), most of which (75.0%) were IDH R132 mutations that can be targeted with Ivosidenib, a drug approved for treating acute myeloid leukemia and cholangiocarcinoma. This evidence concerns the gene IDH1 and central nervous system cancer.